Skye Bioscience/$SKYE
1D1W1MYTD1Y5YMAX
About Skye Bioscience
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
- Ticker
- $SKYE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- San Diego, United States
- Website
- skyebioscience.com
Skye Bioscience Metrics
BasicAdvanced
$7.9M
-
-$10.24
2.99
-
Price and volume
Market cap
$7.9M
Beta
2.99
52-week high
$2.32
52-week low
$1.76
Financial strength
Current ratio
0.95
Quick ratio
0.873
Total debt to equity
-35.943
Interest coverage (TTM)
-8,740.65%
Profitability
EBITDA (TTM)
-47.367
Effective tax rate (TTM)
-0.01%
Management effectiveness
Return on assets (TTM)
-95.06%
Return on equity (TTM)
-233.87%
Valuation
Price to book
-15.68
Price to tangible book (TTM)
-15.68
Price to free cash flow (TTM)
-0.227
Free cash flow yield (TTM)
-440.86%
Free cash flow per share (TTM)
-7.825
Growth
Earnings per share change (TTM)
19.76%
3-year earnings per share growth (CAGR)
-43.90%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.